UK markets close in 6 hours 38 minutes
  • FTSE 100

    7,737.48
    -47.39 (-0.61%)
     
  • FTSE 250

    19,802.00
    -135.20 (-0.68%)
     
  • AIM

    865.28
    -3.88 (-0.45%)
     
  • GBP/EUR

    1.1386
    +0.0007 (+0.06%)
     
  • GBP/USD

    1.2324
    -0.0030 (-0.24%)
     
  • BTC-GBP

    18,589.29
    -344.95 (-1.82%)
     
  • CMC Crypto 200

    519.64
    -18.24 (-3.39%)
     
  • S&P 500

    4,017.77
    -52.79 (-1.30%)
     
  • DOW

    33,717.09
    -260.99 (-0.77%)
     
  • CRUDE OIL

    76.85
    -1.05 (-1.35%)
     
  • GOLD FUTURES

    1,919.80
    -19.40 (-1.00%)
     
  • NIKKEI 225

    27,327.11
    -106.29 (-0.39%)
     
  • HANG SENG

    21,842.33
    -227.40 (-1.03%)
     
  • DAX

    15,040.59
    -85.49 (-0.57%)
     
  • CAC 40

    7,044.99
    -37.02 (-0.52%)
     

Trade Alert: The Founder Of Acer Therapeutics Inc. (NASDAQ:ACER), Christopher Schelling, Has Just Spent US$1m Buying 43% More Shares

Those following along with Acer Therapeutics Inc. (NASDAQ:ACER) will no doubt be intrigued by the recent purchase of shares by Christopher Schelling, Founder of the company, who spent a stonking US$1m on stock at an average price of US$1.22. Not only is that a big swing, but it increased their holding size by 43%, which is definitely great to see.

View our latest analysis for Acer Therapeutics

Acer Therapeutics Insider Transactions Over The Last Year

In fact, the recent purchase by Christopher Schelling was the biggest purchase of Acer Therapeutics shares made by an insider individual in the last twelve months, according to our records. Even though the purchase was made at a significantly lower price than the recent price (US$1.50), we still think insider buying is a positive. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.

Acer Therapeutics insiders may have bought shares in the last year, but they didn't sell any. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
insider-trading-volume

Acer Therapeutics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Does Acer Therapeutics Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. Acer Therapeutics insiders own about US$5.2m worth of shares. That equates to 19% of the company. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

What Might The Insider Transactions At Acer Therapeutics Tell Us?

The recent insider purchases are heartening. We also take confidence from the longer term picture of insider transactions. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Insiders likely see value in Acer Therapeutics shares, given these transactions (along with notable insider ownership of the company). In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Acer Therapeutics. Every company has risks, and we've spotted 5 warning signs for Acer Therapeutics (of which 2 make us uncomfortable!) you should know about.

Of course Acer Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here